With Illumina Acquisition Pending, GRAIL Presents Multi-Cancer Detection Test

This weekend, at the 2021 ASCO Annual Meeting, Menlo Park, Calif.-based GRAIL presented the first data from the interventional PATHFINDER trial of Galleri, its multi-cancer early detection (MCED) blood test. Galleri is now available in the U.S. by prescription.